A Phase 1 Open-Label Multi-Center Safety and Efficacy Study of PRT3789 in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

Brief description of study

This is a study to test a new drug called PRT3789 for safety and effectiveness in treating certain types of advanced or metastatic solid tumors. The study will enroll participants with a specific gene mutation to find the highest non-toxic dose of PRT3789. PRT3789 is designed to inhibit the activity of a protein called SMARCA2. When SMARCA4 is mutated, cancer cells utilize SMARCA2, and thus, by inhibiting the activity of SMARCA2, PRT3789 may help to slow or stop the growth of cancer cells.

Clinical Study Identifier: s22-01405

Principal Investigator: Salman Rafi Punekar.

Other Investigators: Nila Theresa De La Rosa, Scot Niglio, Samantha VanMaanen, Nancy Chan, Jeffrey S. Weber, Elaine Shum, Jessica Wang, Kristen Spencer, Joshua K Sabari, Keriann M Scavone, Cosmin Adrian Tegla, Vamsidhar Velcheti, Kathleen M Madden, David R. Wise, Nina Beri, Janice Mehnert, Douglas K Marks.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies